Savara (SVRA) Capital Expenditures (2010 - 2026)
Savara (SVRA) reported Capital Expenditures of $54000.0 for Q1 2026, up 1700.0% year-over-year from $3000.0 in Q1 2025, and up 2600.0% quarter-over-quarter from $2000.0 in Q4 2025.
Savara (SVRA) Capital Expenditures (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Capital Expenditures data on file, last reported at $54000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $54000.0, up 1700.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $73000.0 (up 305.56% YoY), and the FY2025 annual result was $22000.0, down 12.0% from the prior year.
- Capital Expenditures improved to $54000.0 in Q1 2026 per SVRA's latest filing, from $2000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $225000.0 in Q2 2023 and troughed at -$9000.0 in Q4 2024.
- A 5-year average of $28642.9 and a median of $7000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures plunged 137.5% in 2024, then surged 1700.0% in 2026.
- A 5-year view of Capital Expenditures shows it stood at $4000.0 in 2022, then surged by 500.0% to $24000.0 in 2023, then sank by 137.5% to -$9000.0 in 2024, then surged by 122.22% to $2000.0 in 2025, then jumped by 2600.0% to $54000.0 in 2026.
- Business Quant data shows SVRA's Capital Expenditures at $54000.0 in Q1 2026, $2000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54,000.00 |
| Mar 31, 2026 | 54,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Dec 31, 2023 | 24,000.00 |